UroGen Pharma Ltd. (0XOD.L)

14,16 -0,42 (-2,89%) Alla chiusura: 07:01PM BST

UroGen Pharma Ltd.

400 Alexander Park Drive
4th Floor
Princeton, NJ 08540
United States
(646) 768-9780
https://www.urogen.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 198

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Elizabeth A. Barrett	President, CEO & Director	1,34M	N/D	1962
Mr. Jason Drew Smith	General Counsel, Chief Compliance Officer & Corporate Secretary	864,19k	N/D	1972
Dr. Mark P. Schoenberg M.D.	Chief Medical Officer	639,83k	N/D	1958
Mr. Dong Kim	Chief Financial Officer	546,68k	N/D	1978
Vincent I. Perrone	Senior Director of Investor Relations	N/D	N/D	N/D
Mr. Bryon Wornson	Executive Vice President of Talent, Advocacy & Communications	N/D	N/D	N/D
Dr. Marina Konorty	Executive Vice President of Research & Development and Technical Operations	N/D	N/D	N/D
Mr. Jeffrey Bova M.B.A.	Chief Commercial Officer	N/D	N/D	N/D
Mr. James Ottinger R.ph.	Executive Vice President of Regulatory Affairs & Quality	N/D	N/D	N/D
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D.	Chief Business Officer	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di UroGen Pharma Ltd. al 1 maggio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.